Eco Animal Health ( (GB:EAH) ) has provided an update.
ECO Animal Health Group announced an upcoming R&D Day scheduled for 13 March 2025, where the company’s leadership will present insights into their R&D pipeline to investors and analysts. This event is part of ECO’s strategy to showcase innovations in preventative animal health, aimed at driving long-term value creation and reinforcing its industry position.
More about Eco Animal Health
ECO Animal Health is a global leader in the animal health industry, specializing in the development and marketing of branded veterinary pharmaceuticals. The company’s expertise lies in antibiotics and vaccines for pigs and poultry, with a strong proprietary R&D pipeline. Headquartered in the UK, ECO operates in over 70 countries and employs over 200 people globally. Its flagship product, Aivlosin®, is a patented medication effective against respiratory and intestinal diseases in pigs and poultry.
YTD Price Performance: -12.68%
Average Trading Volume: 55,034
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £42.69M
For a thorough assessment of EAH stock, go to TipRanks’ Stock Analysis page.